% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schrder:169324,
      author       = {R. Schröder and A.-L. Illert and T. Erbes and C.
                      Flotho$^*$ and M. Lübbert$^*$ and J. Duque-Afonso},
      title        = {{T}he epigenetics of breast cancer - {O}pportunities for
                      diagnostics, risk stratification and therapy.},
      journal      = {Epigenetics},
      volume       = {17},
      number       = {6},
      issn         = {1559-2308},
      address      = {Austin, Tex.},
      publisher    = {Landes Bioscience},
      reportid     = {DKFZ-2021-01416},
      pages        = {612-624},
      year         = {2022},
      note         = {2022 Jun;17(6):612-624},
      abstract     = {The stage and molecular pathology-dependent prognosis of
                      breast cancer, the limited treatment options for
                      triple-negative carcinomas, as well as the development of
                      resistance to therapies illustrate the need for improved
                      early diagnosis and the development of new therapeutic
                      approaches. Increasing data suggests that some answers to
                      these challenges could be found in the area of epigenetics.
                      In this study, we focus on the current research of the
                      epigenetics of breast cancer, especially on the potential of
                      epigenetics for clinical application in diagnostics, risk
                      stratification and therapy. The differential DNA methylation
                      status of specific gene regions has been used in the past to
                      differentiate breast cancer cells from normal tissue. New
                      technologies as detection of circulating nucleic acids
                      including microRNAs to early detect breast cancer are
                      emerging. Pattern of DNA methylation and expression of
                      histone-modifying enzymes have been successfully used for
                      risk stratification. However, all these epigenetic
                      biomarkers should be validated in larger clinical studies.
                      Recent preclinical and clinical studies show a therapeutic
                      benefit of epigenetically active drugs for breast cancer
                      entities that are still difficult to treat (triple negative,
                      UICC stage IV). Remarkably, epigenetic therapies combined
                      with chemotherapies or hormone-based therapies represent the
                      most promising strategy. At the current stage, the
                      integration of epigenetic substances into established breast
                      cancer therapy protocols seems to hold the greatest
                      potential for a clinical application of epigenetic
                      research.},
      keywords     = {DNA methylation (Other) / Epigenetic (Other) / breast
                      cancer (Other) / histone acetylation (Other) / histone
                      methylation (Other)},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34159881},
      doi          = {10.1080/15592294.2021.1940644},
      url          = {https://inrepo02.dkfz.de/record/169324},
}